Novoprotein Scientific Inc. (SHA:688137)
113.77
-3.83 (-3.26%)
At close: Nov 17, 2026
Novoprotein Scientific Revenue
Novoprotein Scientific had revenue of 46.24M CNY in the quarter ending September 30, 2026, with 16.29% growth. This brings the company's total for the last twelve months to 159.32M, up 8.14% year-over-year. In the year 2025, Novoprotein Scientific had annual revenue of 146.44M with 14.80% growth. That makes Novoprotein Scientific the 32,808th largest company in the world by revenue and 5,061st in China.
Revenue (ttm)
159.32M
Revenue Growth
+8.14%
P/S Ratio
51.50
Revenue / Employee
250.50K
Employees
696
Market Cap
7.94B
Revenue by Geography
- China 141.14M 96.6%
- Overseas sales 4.93M 3.4%
Fiscal year ended Dec 31, 2025 See the full Novoprotein Scientific breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 146.44M | 18.88M | 14.80% |
| Dec 31, 2024 | 127.56M | -25.64M | -16.73% |
| Dec 31, 2023 | 153.19M | -111.36M | -42.09% |
| Dec 31, 2022 | 264.55M | -77.34M | -22.62% |
| Dec 31, 2021 | 341.90M | 162.05M | 90.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 10.74B |
| Pacific Shuanglin Bio-pharmacy | 2.42B |
| Novogene | 2.30B |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 2.16B |
| Vcanbio Cell & Gene Engineering Corp., | 1.38B |
| Liaoning Chengda Biotechnology | 1.34B |
| Shanghai OPM Biosciences | 822.13M |
| Chongqing Genrix Biopharmaceutical | 800.98M |